+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream



0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream



European Journal of Clinical Pharmacology 42(2): 159-161



The atrophogenic potential of medium-potent topical glucocorticoids is still controversial. In a double-blind controlled trial 24 healthy volunteers either applied 0.25% prednicarbate cream or the corresponding vehicle to one and 0.1% betamethasone-17-valerate cream or 0.05% clobetasol-17-propionate cream to the other forearm twice daily. Skin thickness was regularly assessed during the six week period of application and for further three weeks thereafter, using both the B- and A-mode of a 20 MHz ultrasound scanner. Both betamethasone-17-valerate and clobetasol-17-propionate cream significantly reduced skin thickness as compared to cream base while prednicarbate cream did not. Given that 0.1% betamethasone-17-valerate- and 0.25% prednicarbate cream are reported to be about equipotent in the treatment of atopic eczema the latter preparation shows an increased ratio between its desired anti-inflammatory and its unwanted atrophogenic effect.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039008042

Download citation: RISBibTeXText

PMID: 1618247

DOI: 10.1007/bf00278477


Related references

In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. Journal of Drugs in Dermatology 7(1): 28-32, 2008

Betamethasone dipropionate cream for the treatment of psoriasis. A double-blind comparison with clobetasol propionate cream. Dermatologica 170(3): 152-155, 1985

Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry. Skin Pharmacology 6(3): 187-192, 1993

Fluticasone propionate (0.05%) cream compared to betamethasone valerate (0.12%) cream in the treatment of steroid-responsive dermatoses: a multicentric study. Indian Journal of Dermatology, Venereology and Leprology 62(5): 289-294, 1996

Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Cutis 57(2 Suppl.): 45-50, 1996

A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients. Advanced Biomedical Research 6: 34, 2017

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans. Skin Pharmacology and Applied Skin Physiology 6(3): 187-192, 1993

Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: A comparative flow cytometric study. British Journal of Dermatology 135(3): 379-384, 1996

Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Dermato-Venereologica 82(2): 140, 2002

Comparison of a modified hydrocortisone/urea cream and betamethasone valerate cream in the treatment of dry eczema. Journal of International Medical Research 15(2): 99-105, 1987

Clinical comparison of desonide cream with betamethasone valerate cream. A double-blind randomized study. International Journal of Dermatology 11(2): 73-76, 1972

Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Dermato-Venereologica 87(2): 167-168, 2007

A double-blind comparison between a new trihalogenated dermatocorticosteroid (halometasone) cream and clobetasol 17-propionate (Dermovate) cream. British Journal of Clinical Practice 36(5): 192-196, 1982

Clobetasol propionate cream versus halcinonide cream in psoriasis. International Journal of Dermatology 25(5): 332-333, 1986

Double-blind evaluation of the effectiveness and tolerance of tipredane cream and betamethasone valerate cream in patients with psoriasis. Giornale Italiano di Dermatologia E Venereologia 123(9): Il-Li, 1988